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Abstract
Aims: To compare quality of life (QOL) for patients with irritable bowel syndrome (IBS) between
the U.S. and Japan, it is indispensable to develop common instruments. The IBS-QOL, which is
widely used in Western countries, was translated into Japanese as there has been a lack of Japanese
disease-specific QOL measures for IBS.
Methods: The original 34 items of the IBS-QOL were translated from English into Japanese
through two independent forward translations, resolution, back translation, and resolution of
differences. Forty nine patients who had GI symptoms but did not have any organic diseases
(including 30 IBS patients diagnosed by Rome II criteria) were recruited from Tohoku University
Hospital in Sendai, Japan and completed a Japanese version of the IBS-QOL (IBS-QOL-J)
concomitant with a Japanese version of the IBS severity index (IBSSI-J) twice within 7–14 days.
Results: The IBS-QOL-J demonstrated high internal consistency (Cronbach's alpha; 0.96) and high
reproducibility (intraclass correlation coefficient; 0.92, p < 0.001). Convergent analyses confirmed
that the overall score of IBS-QOL-J was significantly correlated with overall severity of IBS
symptoms on the IBSSI-J (r = -0.36, p = 0.01) and with the individual items on the IBSSI-J that assess
interference with life in general (r = -0.47, p = 0.001) and dissatisfaction with bowel habits (r = -
0.32, p < 0.05). Eight patients who reported continuous abdominal pain in the past 6 months had
significantly lower scores in the IBS-QOL-J than those who did not (53.7 +- 12.7 vs. 73.6 +- 19.5,
p < 0.01). Age, sex, education or marital status did not affect scores on the measure.
Conclusion: The IBS-QOL-J is a reliable instrument to assess the disease-specific QOL for IBS.
Considering cross-cultural comparison, this measure is likely to be a valuable tool to investigate the
QOL in Japanese patients with IBS.
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Background
Irritable bowel syndrome (IBS) is a common gastrointes-
tinal disorder and is often associated with psychological
distress [1,2]. People with IBS have a significantly dimin-
ished quality of life (QOL) [3,4]. Even though a large per-
centage of subjects with IBS do not seek medical care
(approximately 75%) [5], IBS is associated with signifi-
cantly more absences from work and school and with
impaired QOL [3,4]. The impact on QOL in patients with
IBS is often underestimated by friends and family mem-
bers, and even by the patient's doctors because they are
not disabled in any obvious way and there is no apparent
impact on life expectancy.
How much of a burden illness is on an individual's life
depends on several factors. It is becoming recognized that
assessment of QOL associated with a person's illness
should be taken into account in order to understand the
burden illness on several medical conditions. We have
demonstrated that both IBS patients and IBS non-consult-
ers report not only more severe gastrointestinal symptoms
and psychological distress but also more impaired health-
related QOL than people who do not have IBS, as has
been reported in other countries [6]. In contrast to reports
form the United States [7], IBS patients were not different
from IBS non-consulters for physical and psychological
QOL scores on the SF-36 [8].
Although generic instruments like the SF-36 offer the
opportunity to compare the impacts of different condi-
tions on health status [9,10], disease-specific measures are
more sensitive than generic measures of QOL to the
effects of illness and the impact of treatment [9]. Within
the gastroenterology field, disease-specific quality-of-life
measures have been developed primarily for inflamma-
tory bowel disease [11].
Patrick and Drossman developed and validated a specific
QOL measure, the IBS-QOL, to assess the impairment of
QOL in IBS [12]. The instrument defines "perceived qual-
ity of life" according to a needs-based model that consid-
ers QOL as the degree to which all or most needs are met
[13]. It reveals patients' predominant concerns with high
degree of specificity and attribution to the bowel symp-
toms associated with the condition [12]. Furthermore,
they confirmed that this instrument is responsive to treat-
ment in a clinical population of patients with FBD [14].
This instrument has been translated into several languages
(i.e. Dutch, Spanish, French, Chinese and Korean) and is
widely used [15-21].
There have been no studies on the cross-cultural differ-
ences in IBS between the U.S. and Japan due to the lack of
common disease-related instruments. To compare QOL
in patients with IBS between these countries, it is indis-
pensable to develop disease-specific QOL measurements
like the IBS-QOL in Japanese. The aim of this study was to
test the reliability and validity of a Japanese version of the
IBS-QOL (IBS-QOL-J).
Methods
Forty-nine consecutive patients (27 female and 22 male)
who suffered with chronic or recurrent abdominal pain,
abdominal discomfort and/or altered bowel habit in
Tohoku University Hospital, Sendai, Japan were invited to
participate. All the participants completed the IBS-QOL-J
(see Additional file 1) concomitant with a Japanese ver-
sion of the IBSSI (IBSSI-J) [22] twice between 7–14 days
interval to confirm the test-retest reproducibility. The Jap-
anese version of the Rome II modular questionnaire, in
conjunction with medical evaluation to exclude alterna-
tive diagnosis, was used to diagnose IBS [22]. None of the
participants had any organic GI diseases or any other
severe physical and/or psychological disorders. Age, sex,
marital status, education, race, number of visits to physi-
cians due to GI symptoms, and existence of continuous or
nearly continuous abdominal pain in the past 6 months
were also investigated (Table 1). This study was approved
by the Tohoku University Ethics Committee (No. 2004-
061). All the participants gave written informed consent.
The Rome II modular questionnaire (RMIIQ) has been
used as a diagnostic instrument for functional GI disor-
ders according to Rome II diagnostic criteria [23]. This
instrument includes 4 key questions used to define IBS
plus 11 supportive items that address bowel habits. IBS is
defined by abdominal discomfort or pain that was present
during at least 3 weeks in the last 3 months and that has
two of three features: (1) Relieved with defecation; and/or
(2) onset associated with a change in frequency of stool;
and/or (3) onset associated with a change in form
(appearance) of stool [22,23]. Subtypes of IBS were
assessed by predominant stool pattern; hard or lumpy
stools >25% and loose (mushy) or watery stools <25% of
bowel movements as IBS with constipation (IBS-C), and
loose (mushy) or watery stools >25% and hard or lumpy
stools <25% of bowel movements as IBS with diarrhea
(IBS-D) [24].
The IBS Severity Index (IBSSI) was developed and vali-
dated in the U.K. to assess the major GI symptoms in IBS
[25]. This scoring system is simple and consists of only 5
items each with 100-point scale (0, none; 100, worst).
These items are severity and duration of abdominal pain,
severity of abdominal distension, dissatisfaction with
bowel habits (bowel score) and interference with life in
general (QOL). The maximum total score is 500 points
[22,25]. Recently, these two instruments have been trans-
lated into Japanese and validated for Japanese patientsBioPsychoSocial Medicine 2007, 1:6 http://www.bpsmedicine.com/content/1/1/6
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with functional bowel disorders (FBD) by our research
group [22].
The IBS-QOL consists of 34 items with 5-point response
scales (0 to 4). The IBS-QOL is scored for 8 subscales; dys-
phoria (8 items), interference with activity (7 items), body
image (4 items), health worry (3 items), food avoidance
(3 items), social reaction (4 items), sexual concerns (2
items) and relationships (3 items) [12]. Higher values
indicate better QOL after converting the raw score on the
IBS-QOL into 0 to 100 points. The process for the valida-
tion study of the IBS-QOL-J was as follows: The original
34 items of the IBS-QOL were translated from English
into Japanese through two independent forward transla-
tions (by M.K. and S.F.), resolution, back translation by a
native speaker of English, and resolution of differences. As
a result of the discussion among the translators and the
authors of the original version (D.A.D. and W.E.W.), no
obvious difference of contents was found between the
original and the back-translated versions.
Cronbach's alpha was calculated to assess the internal
consistency reliability. A high internal consistency sug-
gests that the scale is measuring a single construct. Repro-
ducibility was assessed by comparing the total IBS-QOL-J
score at baseline to a second one later. Convergent and
discriminant validity involve comparing logically related
measures to see if they are correlated more strongly (con-
vergent) or more weakly (discriminant). The overall score
for the IBSSI-J and the scores for the 5 components at
baseline were used to assess convergent validity of the IBS-
QOL-J. Strengths of association as the test-retest reliability
or the convergent/construct validity were tested by a sim-
ple regression analysis, Pearson's correlation coefficient.
Multiple regression analysis was used to confirm the rela-
tionships among the IBS-QOL-J score, age, gender, educa-
tion and marital status.
Results
Characteristics of the participants are shown in Table 1.
The mean age with standard deviation (SD) of partici-
pants was 38 +- 15 years (19–79 years old). Thirty patients
were diagnosed as IBS by the Japanese version of Rome II
modular questionnaire, and the rest of them were consid-
ered to have other FBD. Six patients diagnosed as IBS were
constipation predominant (IBS-C), 14 were diarrhea pre-
dominant (IBS-D) and 10 were not classifiable as either.
Overall score of the IBS-QOL-J demonstrated high repro-
ducibility (intraclass correlation coefficient, 0.92, p <
0.001) and high internal consistency (Cronbach's alpha,
Table 1: Characteristics of the sample (n = 49)
Sex
Male 22
Female 27
Age (yrs, mean ± SD) 38 ±15
Race
Japanese 49
Others 0
Marital status
Single living alone 10
Single living with a partner 14
Married 24
Divorced 1
Education
8th grade or less 3
Some high school 1
High school graduate 19
Some college or technical school 8
College graduate 18
Diagnosis by Rome II criteria
Irritable bowel syndrome (IBS) 30
IBS subtypes of bowel habit
IBS with constipation (IBS-C) 6
IBS with diarrhea (IBS-D) 14
Mixed or unspecified IBS 10
Other functional bowel disorders (FBD) 19
Classification of symptom severity by IBSSI
Mild 15
Moderate 22
Severe 12
IBSSI: IBS severity index. Data were expressed as number of subjects except for age.BioPsychoSocial Medicine 2007, 1:6 http://www.bpsmedicine.com/content/1/1/6
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0.96). Each individual score on the IBS-QOL-J also
showed high reproducibility and relatively high internal
consistency (Table 2). Response to the individual items
significantly correlated with overall score of the IBS-QOL-
J except for Q5 from the body image domain and Q32
from the health worry domain (Table 3).
Validity of the IBS-QOL-J was confirmed by the significant
correlations with measures of disease severity. The overall
score of IBS-QOL-J was significantly correlated with over-
all severity of IBS symptoms on the IBSSI-J (r = -0.36, p =
0.01) and with the individual questions on the IBSSI-J
that assess interference with life in general (r = -0.47, p =
0.001) and dissatisfaction with bowel habits (r = -0.32, p
= 0.03, Table 4). The correlations between the overall
score of the IBS-QOL-J and individual scores of abdomi-
nal pain (severity and duration) were weaker and were not
statistically significant. Abdominal distension (severity)
on the IBSSI-J was correlated to quality of life was as meas-
ured by the IBS-QOL-J.
Linear regression analyses revealed that the number of
physician visits in the past 6 months was significantly
associated with the overall score of IBS-QOL-J (r = -0.33,
p < 0.05) but not with the overall severity score (r = 0.19,
p > 0.1). Eight patients who reported continuous or nearly
continuous abdominal pain in the past 6 months had sig-
nificantly lower scores in the IBS-QOL-J than those who
did not (53.7 +- 12.7 vs. 73.6 +- 19.5, p < 0.01, Fig. 1).
There was no significant difference in the overall score or
each of individual score on the IBS-QOL-J between
patients who were diagnosed as IBS by the RIIMQ and
those who were not (namely, the other FBD) in the partic-
ipants (Table 5). Age, sex, education or marital status did
not affect scores on the measure as a predictor variable.
Most of the IBS-QOL-J scores in Japanese patients with IBS
were quite comparable to those in the English version of
the IBS-QOL in IBS patients in the U.S. There was no sig-
nificant difference in the overall or each individual score
on the IBS-QOL-J between subtypes of bowel movement
in 30 patients diagnosed as IBS.
Discussion
The Japanese version of the IBS-QOL (IBS-QOL-J) instru-
ment was confirmed to be reliable and valid. This disease-
specific QOL measurement shows high internal consist-
ency for the overall score. The reproducibility over the
two-week study period was excellent. The original version
of the IBS-QOL has previously been shown to have high
internal consistency and reproducibility [12]. On this
original instrument, discriminant and convergent validity
[12] and responsiveness [14] were also demonstrated. Not
only severity of symptoms but also psychological well-
being predicted this score [26]. Although Cronbach's
alpha scores for most of the individual domains also
resulted high (Table 2), the factor analysis revealed that a
couple of individual items affected rather low alpha scores
for the specific domains (Table 3). Further larger studies
should be needed to confirm whether cross-cultural dif-
ferences in patients' concerns might be associated with the
inconsistencies in the present study.
Disease-specific quality of life instruments are sensitive
and responsive to measuring treatment response over
time; thus, they are especially useful in clinical research
trials in which health status is analyzed [9]. Several dis-
ease-specific QOL measures for IBS or functional GI disor-
ders have been developed (e.g. IBSQOL developed by
Hahn et al. [27]). However, in most instruments, their
responsiveness has not been demonstrated except for the
IBS-QOL. In a systematic review by Bijkerk et al, it was
shown that the IBS-QOL is the best of the five IBS-specific
QOL scores to establish changes in health-related QOL
[28]. On the other hands, the IBS severity index (IBSSI) is
considered to be the best choice for a detailed IBS symp-
tom assessment [28].
Table 2: Reliability and validity for the overall and individual scores on the IBS-QOL-J
IBS-QOL Score (mean ± SD) (Time 1) Cronbach's alpha (Time 1) Intraclass correlation 
coefficient (ICC)
Overall scale 70.3 ± 19.9 0.96 0.92a
Subscales (number of items)
Dysphoria (8) 61.5 ± 27.1 0.94 0.88a
Interference with activity (7) 66.4 ± 24.7 0.86 0.94a
Body image (4) 82.9 ± 18.0 0.56 0.90a
Health worry (3) 76.0 ± 18.6 0.48 0.81a
Food avoidance (3) 59.5 ± 28.2 0.83 0.92a
Social reaction (4) 78.2 ± 19.2 0.76 0.85a
Sexual concerns (2) 84.7 ± 19.6 0.61 0.80a
Relationships (3) 71.3 ± 25.6 0.74 0.87a
ap < 0.001; Pearson's correlation coefficient.BioPsychoSocial Medicine 2007, 1:6 http://www.bpsmedicine.com/content/1/1/6
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Recently, we have translated the Rome II modular ques-
tionnaire for IBS and the IBSSI into Japanese and have
confirmed reliability and reproducibility in patients with
functional bowel disorders (FBD) [22]. Our results in the
present study show that the IBS-QOL-J is strongly corre-
lated with the self-rating scales for the overall severity
measure. Besides, patients who reported continuous or
nearly continuous abdominal pain showed a lower over-
all score on the IBS-QOL-J than those who did not. On the
other hand, our study did not confirm that there are sig-
nificant differences in the QOL score among subtypes of
bowel movement in patients with IBS. These results sug-
gest that IBS patients who have abdominal pain continu-
ously may have more impaired QOL despite predominant
stool patterns. Furthermore, patients considered as fre-
quent consulters according to a previous systemic review
[29] show lower scores in the IBS-QOL-J. Previous reports
on the original IBS-QOL show a significant association
between the IBS-QOL and number of visit to physicians
for IBS problems [14]. Thus, the findings of the present
study are consistent with those of the original version of
the disease-specific QOL measure for IBS.
The mean overall score of the IBS-QOL-J in patients with
IBS was similar with that of original version [12] meas-
ured in the U.S. (68.2 vs. 63.2 points) despite different
diagnostic criteria (Rome II vs. Rome I) and subject popu-
lation (tertiary care vs. GI clinic plus advertisement). The
mean overall score of the IBS-QOL-J in patients with IBS
also showed a similar result with that measured by the
Korean version of the IBS-QOL in South Korea [21]. Nev-
ertheless, the mean individual scores of body image (80.0
vs. 62.5), health worry (73.1 vs. 59.2), food avoidance
(55.3 vs. 43.4) and sexual concerns (89.2 vs. 73.5) on the
Japanese version were over 10-point higher [12] (see
Table 5).
Our results failed to confirm that the overall IBS-QOL-J
score is significantly associated with the individual scores
of the abdominal pain severity or pain duration in the
Table 4: Correlations between overall score of the IBS-QOL-J and overall and individual scores of the IBSSI-J
IBS-QOL-J
Correlation Significance
IBSSI-J
Overall -0.36 0.01
Abdominal pain (severity) -0.21 N.S.
Abdominal pain (duration) -0.23 N.S.
Abdominal distension -0.00 N.S.
Bowel movement -0.32 0.03
Quality of life -0.47 0.001
Table 3: Evaluation of the utility of individual items on the IBS-QOL-J
Domain Item Correlation Domain Item Correlation
Dysphoria Q1 -0.83** Health worry Q4 -0.56**
Q6 -0.86** Q15 -0.74**
Q7 -0.82** Q32 -0.19
Q9 -0.76** Food avoidance Q11 -0.45**
Q10 -0.75** Q23 -0.55**
Q13 -0.72** Q28 -0.59**
Q16 -0.80** Social reaction Q2 -0.60**
Q30 -0.89** Q14 -0.54**
Interference with Q3 -0.60** Q17 -0.60**
activity Q18 -0.78** Q34 -0.79**
Q19 -0.60** Relationships Q8 -0.66**
Q22 -0.70** Q24 -0.70**
Q27 -0.75** Q33 -0.70**
Q29 -0.73** Body image Q5 -0.10
Q31 -0.53** Q21 -0.76**
Sexual Q12 -0.30* Q25 -0.61**
Q20 -0.47** Q26 -0.68**
*p < 0.05, **p < 0.01; Pearson's correlation coefficient between individual items and overall score of the IBS-QOL-J.BioPsychoSocial Medicine 2007, 1:6 http://www.bpsmedicine.com/content/1/1/6
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IBSSI-J. We do not believe that gastrointestinal (GI) symp-
toms of the patients in this study were less severe because
more than two-thirds demonstrated moderate to severe
symptoms on the IBSSI-J according to the severity classifi-
cation system on the original version [25] (see Table 1).
Despite 41 of 49 patients had taken medical treatment for
their GI symptoms including antispasmodic agents and
antidepressants, they did not report lower abdominal
pain scores compared with the rest of the patients who
had not in the present study.
It has been demonstrated that the Japanese subjects are
less prone to be accepting of pain behaviors [30] and
express their sexual activities to someone [31] compared
with people in the Western countries. There was no differ-
ence in the individual score of sexual concerns between
married and unmarried patients in this study, in fact.
When the sexual concerns are assessed in the Japanese
patients, it should be taken into account that they may
hesitate or avoid expression of such topics even if they
have any sexual problems. Although we could not com-
pare differences in these scores directly, cross-cultural dif-
ference between the countries (e.g. race, food, belief,
social milieu and health-care system) might affect some
dimensions of perception for the health-related QOL in
patients with IBS.
The IBS-QOL-J appears to be a reliable instrument to
assess the disease-specific QOL for IBS in Japanese
patients. However, this validation study was cross-sec-
tional, and thus could not investigate responsiveness.
Moreover, our sample was relatively small and recruited
from only the referred FBD patients. Further validation
studies are warranted to investigate reliability and validity
on the Japanese version of the IBS-QOL. It is important to
assess not only severity of symptoms but also disease-spe-
cific QOL when considering the strategy for treatment for
IBS since no biological measure is available for assessing
IBS. Considering cross-cultural comparisons, these instru-
Table 5: Comparison of the IBS-QOL between Japan and the U.S
Score (mean ± SD)
IBS (Japan) Other FBD (Japan) IBS* (U.S.)
Number 30 19 155
Female (%) 18 (60) 9 (47) 138 (89)
Age (yrs) 39 ± 17 37 ± 12 39 ± 12
IBSSI (Overall) 250 ± 95.5a 172 ± 89.8 - b
IBS-QOL
Overall 68.2 ± 19.7 73.6 ± 20.2 63.2 ± 18.5
Dysphoria 61.0 ± 26.8 62.2 ± 28.4 63.1 ± 23.9
Interference with activity 62.3 ± 25.8 72.9 ± 21.9 63.1 ± 22.3
Body image 80.0 ± 18.0 87.5 ± 17.4 62.5 ± 24.3
Health worry 73.1 ± 19.4 80.7 ± 16.7 59.2 ± 24.6
Food avoidance 55.3 ± 27.2 66.2 ± 29.1 43.4 ± 26.7
Social reaction 77.1 ± 18.9 79.9 ± 21.4 69.4 ± 22.9
Sexual concerns 89.2 ± 22.9 87.5 ± 13.2 73.5 ± 27.6
Relationships 72.2 ± 23.0 67.7 ± 29.8 72.3 ± 21.7
*IBS was diagnosed by Rome I criteria, data from Patrick, et al, 1998 (with permission, ref. 12). ap < 0.01 vs other FBD. bIBSSI was not investigated. 
Higher values indicate better QOL score for the IBS-QOL.
Comparison of the IBS-QOL-J scores between patients who  reported continuous or nearly continuous abdominal pain  and those who did not Figure 1
Comparison of the IBS-QOL-J scores between patients who 
reported continuous or nearly continuous abdominal pain 
and those who did not. Results were expressed as mean with 
standard deviation of the overall scores on the IBS-QOL-J. 
Patients who reported continuous abdominal pain showed a 
significant lower score than those who did not (*p < 0.01, 
Mann-Whitney U test).
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ments are likely to be a valuable tool to investigate the
QOL in Japanese patients with IBS.
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